April 24, 2025

SGO’s President-Elect Brings Professional Experience and Passion to Her New Role

Society of Gynecologic Oncology (SGO) President-Elect Karen Lu, MD, assumed her official duties on March 17, 2025. Dr. Lu, who is also Executive Vice President and Physician-in-Chief at Moffitt Cance...

The ASCO Post

March 28, 2025

Radiotherapy Alone Following Radical Hysterectomy for Cervical Cancer: Should It Remain the Standard of Care?

The phase III NRG Oncology GOG-0263 trial—results of which were presented during the Plenary Session of the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women’s Cancer—examined whether...

The ASCO Post

March 29, 2023

Positive Outcomes Demonstrated in Patients With Ovarian Cancer Treated With Olaparib Prior to Surgical Intervention and Subsequent Chemotherapy

Treatment with the poly (ADP-ribose) polymerase inhibitor olaparib prior to surgical intervention and chemotherapy has demonstrated the potential for favorable surgical options, manageable adverse eve...

The ASCO Post

March 30, 2023

Time-Related and Financial Burdens May Impact Quality of Life for Patients With Gynecologic Cancer

Time-related and financial burdens may be detrimental to the quality of life of patients with gynecologic cancer as well as cancer survivors, according to the findings from two new studies presented b...

The ASCO Post

March 28, 2024

Chemoradiotherapy With or Without Pembrolizumab for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer

The phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial investigated the efficacy and safety of adding pembrolizumab to chemoradiotherapy in patients with newly diagnosed, high-risk, locally advanced cerv...

The ASCO Post

February 19, 2025

Pembrolizumab in Previously Treated Advanced Clear Cell Gynecological Cancers

“Advanced clear cell gynecological cancers (CCGCs) have a poor prognosis, with response rates to second-line chemotherapy less than 8%. Preliminary clinical activity with PD-1 inhibitors reported in C...

The ASCO Post

May 11, 2023

Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma

A new Wee1 kinase inhibitor, adavosertib, showed promising antitumor activity but also raised safety concerns in patients with recurrent or persistent uterine serous carcinoma. The findings were presented by Joyce F. Liu, MD, MPH at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer.

The ASCO Post

May 11, 2023

Expert Point of View: Amanda Nickles Fader, MD

Dr. Amanda Nickles Fader provides insights into GOG 3026, a groundbreaking study offering new hope for low-grade serous ovarian carcinoma with potential implications in treatment paradigms for advanced-stage malignancies.

The ASCO Post

May 25, 2023

Expert Point of View: Kathleen Moore, MD, MS

Dr. Kathleen Moore discusses the impact of targeted radiotherapy and systemic therapies on improving outcomes in endometrial cancer.

The ASCO Post